Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exchange losses and legal expenses drag down Orchid's Q3

This article was originally published in Scrip

Executive Summary

Orchid Chemicals and Pharmaceuticals has reported a net loss of Rs168.6 million ($3.6 million) for the third quarter ended December 31st, 2009, against a loss of Rs63.1 million for the same period in the previous year. The figure was dragged down by exchange rate losses and legal expenses incurred for a challenge concerning piperacillin and tazobactam for injection (a generic version of Wyeth's Zosyn) in the US.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts